Summary of Significant Accounting Policies (Tables)
|
6 Months Ended |
Jun. 30, 2021 |
| Accounting Policies [Abstract] |
|
| Schedule of cash and cash equivalents |
| | |
June 30, 2021 | | |
December 31, 2020 | |
| Cash and cash equivalents | |
$ | 73,093,132 | | |
$ | 41,905,469 | |
Restricted cash, short-term and long-term | |
| 240,083 | | |
| 191,314 | |
| Total cash, cash equivalents and restricted cash | |
$ | 73,333,215 | | |
$ | 42,096,783 | |
|
| Schedule of marketable securities |
June 30, 2021: | |
Amortized
Cost | | |
Gross
Unrealized
Losses | | |
Gross
Unrealized
Gains | | |
Fair Value | |
| Money Market Funds included in Cash Equivalents | |
$ | 17,478,369 | | |
$ | - | | |
$ | - | | |
$ | 17,478,369 | |
| Corporate Securities | |
| 3,561,926 | | |
| (1,584 | ) | |
| | | |
| 3,560,342 | |
| Commercial Paper | |
| 1,598,744 | | |
| - | | |
| 267 | | |
| 1,599,011 | |
| Subtotal | |
| 5,160,670 | | |
| (1,584 | ) | |
| 267 | | |
| 5,159,353 | |
| Total June 30, 2021 | |
$ | 22,639,039 | | |
$ | (1,584 | ) | |
$ | 267 | | |
$ | 22,637,722 | |
| December 31, 2020: | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds included in Cash Equivalents | |
$ | 3,182,762 | | |
$ | (81 | ) | |
$ | 8 | | |
$ | 3,182,689 | |
| Corporate Securities | |
| 3,565,501 | | |
| (1,005 | ) | |
| 3 | | |
| 3,564,499 | |
| Commercial Paper | |
| 879,501 | | |
| - | | |
| 72 | | |
| 879,573 | |
| Subtotal | |
| 4,445,002 | | |
| (1,005 | ) | |
| 75 | | |
| 4,444,072 | |
| Total December 31, 2020 | |
$ | 7,627,764 | | |
$ | (1,086 | ) | |
$ | 83 | | |
$ | 7,626,761 | |
|
| Schedule of carrying and fair value of financial assets |
| June 30, 2021: | |
Carrying Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| Money Market Funds and Cash Equivalents | |
$ | 17,478,369 | | |
$ | 17,478,369 | | |
$ | - | | |
$ | - | |
| Corporate Securities | |
| 3,560,342 | | |
| - | | |
| 3,560,342 | | |
| - | |
| Commercial Paper | |
| 1,599,011 | | |
| - | | |
| 1,599,011 | | |
| - | |
| Subtotal | |
| 5,159,353 | | |
| - | | |
| 5,159,353 | | |
$ | - | |
| Total June 30, 2021 | |
$ | 22,637,722 | | |
$ | 17,478,369 | | |
$ | 5,159,353 | | |
$ | - | |
| December 31, 2020: | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds and Cash Equivalents | |
$ | 3,182,689 | | |
$ | 3,182,689 | | |
$ | - | | |
$ | - | |
| Corporate Securities | |
| 3,564,499 | | |
| - | | |
| 3,564,499 | | |
| - | |
| Commercial Paper | |
| 879,573 | | |
| - | | |
| 879,573 | | |
| - | |
| Subtotal | |
| 4,444,072 | | |
| - | | |
| 4,444,072 | | |
| - | |
| Total December 31, 2020 | |
$ | 7,626,761 | | |
$ | 3,182,689 | | |
$ | 4,444,072 | | |
$ | - | |
|
| Schedule of inventories |
| | |
June 30,
2021 | | |
December 31,
2020 | |
| Finished goods | |
$ | 245,668 | | |
$ | 317,733 | |
| Inventory reserve | |
| (172,941 | ) | |
| (174,169 | ) |
| Total | |
$ | 72,727 | | |
$ | 143,564 | |
|
| Schedule of accrued expenses |
| | |
June 30,
2021 | | |
December 31,
2020 | |
| Professional and consulting fees | |
$ | 234,041 | | |
$ | 146,129 | |
| Accrued payroll and payroll taxes | |
| 1,432,414 | | |
| 2,490,441 | |
| Clinical trial related | |
| 1,000 | | |
| 2,187 | |
| Manufacturing development related | |
| 278,305 | | |
| 143,780 | |
| Other | |
| 118,609 | | |
| 141,814 | |
| Total | |
$ | 2,064,369 | | |
$ | 2,924,351 | |
|
| Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share |
| | |
Six Months Ended June 30, | |
| | |
2021 | | |
2020 | |
| | |
(Number of Shares of
Common Stock Issuable) | |
| Series C non-voting preferred stock | |
| 4,000 | | |
| 104,000 | |
| Series E non-voting preferred stock | |
| 391,953 | | |
| 391,953 | |
| Series G non-voting preferred stock | |
| 5,004,069 | | |
| 5,560,137 | |
| Restricted stock units | |
| - | | |
| 105 | |
| Shares issuable for payment of deferred board compensation | |
| 48,909 | | |
| 40,556 | |
| Shares underlying outstanding warrants | |
| 56,455 | | |
| 183,148 | |
| Shares underlying outstanding stock options | |
| 3,765,746 | | |
| 2,300,937 | |
| Total potentially dilutive shares | |
| 9,271,132 | | |
| 8,580,836 | |
|